REG - Indivior PLC - Indivior Appoints Tony Kingsley to the Board

IndiviorAnnouncement

25/06/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nRSY2545Oa&default-theme=true

RNS Number : 2545O  Indivior PLC  25 June 2025

 

Indivior Appoints Tony Kingsley to the Board of Directors

Richmond, VA, June 24, 2025 - Indivior PLC (Nasdaq / LSE: INDV) today
announced the appointment of Tony Kingsley to the Board of Directors as an
Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was
appointed pursuant to Indivior's relationship agreement with affiliates of
Oaktree Capital Management, L.P., who supported his appointment.

Tony Kingsley is an accomplished biopharmaceutical executive with a
distinguished track record of building and leading organizations across
multiple scientific disciplines, therapeutic areas, and stages of development
and commercialization.

"I am pleased to announce Tony's appointment to the Indivior Board. He is an
experienced biopharmaceutical leader recognized for his strategic vision,
operational expertise, and ability to drive growth in complex, regulated
environments," said David Wheadon, M.D., Chair of the Board of Indivior.
"Tony's significant commercial and clinical development experience will be
invaluable to Indivior as we work to realize the full potential of
SUBLOCADE(®) and deliver value to all Indivior stakeholders."

"Indivior has a long and successful track record of addressing the opioid use
disorder with its portfolio of medicines to make meaningful recovery
possible," said Mr. Kingsley. "I look forward to working closely with the
Board and management team to advance Indivior's mission and strengthen its
position as a leader in delivering life-transforming treatments for opioid use
disorder."

Mr. Kingsley currently serves as CEO and Director of Stablix, Inc., a
biotechnology company pioneering deubiquitination therapeutics as novel
modality. Prior to joining Stablix, Mr. Kingsley was President and CEO of
Scholar Rock (Nasdaq: SRRK), a clinical-stage biopharmaceutical company
focused on the treatment of serious diseases driven by protein growth factors.
Previously, he led TARIS Bio as President and CEO, guiding the company through
its acquisition by Janssen Pharmaceuticals in 2019. Earlier in his career, Mr.
Kingsley held a series of senior leadership roles, including President and
Chief Operating Officer at The Medicines Company (Nasdaq: MDCO) and Executive
Vice President of Global Commercial Operations at Biogen (Nasdaq: BIIB), where
he oversaw the launch and growth of multiple therapies in neurology and
hemophilia. Prior to this, he held numerous senior general management roles in
devices and diagnostics and was a partner at McKinsey & Company.

Mr. Kingsley graduated magna cum laude from Dartmouth College and received an
M.B.A. from Harvard Business School.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat opioid use disorder (OUD). Our vision
is that all patients around the world will have access to evidence-based
treatment for OUD and we are dedicated to transforming OUD from a global human
crisis to a recognized and treated chronic disease. Building on its global
portfolio of OUD treatments, Indivior has a pipeline of product candidates
designed to expand on its heritage in this category. Headquartered
in the United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in over 30
countries worldwide. Visit www.indivior.com (https://www.indivior.com/en)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://www.linkedin.com/company/indivior/?viewAsMember=true) .

 

For Further Information

 Jason Thompson  VP, Investor Relations                      +1 804 402 7123

                 Indivior PLC                                jason.thompson@indivior.com

 Tim Owens       Director, Investor Relations Indivior PLC   +1 804 263 3978

                                                             timothy.owens@indivior.com

 

 

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDLSUDDGUS